In a remarkable incursion into the pharmaceutical arena, Big Pharma finds itself targeted by growing antitrust class action lawsuits for allegedly misusing patents. Much of these allegations assert the intentional thwarting of generic alternatives in a bid to retain monopoly control over specific drug-device combinations.
One such lawsuit cites Teva Pharmaceutical Industries, a global leader in the industry, as having stifled potential competitors by exploiting the nuanced regulations in place for drug-device combinations. The claimants articulate that the current laws do not allow for a generic substitution unless it has attained approval for that specific combination. According to the claimants, this regulatory quirk has allegedly been subverted to hinder the proliferation of generic counterparts, thereby positioning the company as the undeterred provider of QVAR – the drug-device combination at the center of the case.
Manifesting as the most recent entry in a series of similar lawsuits against pharmaceutical conglomerates, this particular case reflects an escalating trend. Challenging doctrines of intellectual property within the ambit of pharmaceuticals, and resonating with larger discussions on market competition and the legality of patent strategies, such disputes are becoming integral parts of the changing legal discourse around healthcare and access to medication.
For a detailed account of the allegations and the consequent legal proceedings in the case against Teva, follow the original coverage from Law.com.